212 related articles for article (PubMed ID: 11602813)
1. Acute hemodynamic effects of beta-blockers in patients with severe congestive heart failure: comparison of celiprolol and esmolol.
Felix SB; Stangl V; Kieback A; Doerffel W; Staudt A; Wernecke KD; Baumann G; Stangl K
J Cardiovasc Pharmacol; 2001 Nov; 38(5):666-71. PubMed ID: 11602813
[TBL] [Abstract][Full Text] [Related]
2. Beta blockers in heart failure: a comparison of a vasodilating beta blocker with metoprolol.
Sanderson JE; Chan SK; Yu CM; Yeung LY; Chan WM; Raymond K; Chan KW; Woo KS
Heart; 1998 Jan; 79(1):86-92. PubMed ID: 9505927
[TBL] [Abstract][Full Text] [Related]
3. Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker.
Sanderson JE; Chan WW; Hung YT; Chan SK; Shum IO; Raymond K; Woo KS
Br Heart J; 1995 Nov; 74(5):502-7. PubMed ID: 8562234
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the potassium channel blocker tedisamil with the beta-adrenoceptor blocker esmolol and the calcium antagonist gallopamil in patients with coronary artery disease.
Mitrovic V; Oehm E; Thormann J; Pitschner H; Haberbosch W
Clin Cardiol; 1998 Jul; 21(7):492-502. PubMed ID: 9669058
[TBL] [Abstract][Full Text] [Related]
5. Intravenous esmolol is well tolerated in elderly patients with heart failure in the early phase of non-ST elevation myocardial infarction.
Koutouzis M; Nikolidakis S; Grigoriadis A; Koutsogeorgis D; Kyriakides ZS
Drugs Aging; 2006; 23(8):673-80. PubMed ID: 16964989
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with esmolol, a short-acting beta-adrenergic blocker in cardiac arrhythmias and myocardial ischemia.
Sung RJ; Blanski L; Kirshenbaum J; MacCosbe P; Turlapaty P; Laddu AR
J Clin Pharmacol; 1986 Mar; 26(S1):A15-A26. PubMed ID: 2870082
[TBL] [Abstract][Full Text] [Related]
7. Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol.
Barbier GH; Shettigar UR; Appunn DO
Int J Clin Pharmacol Ther; 1995 Apr; 33(4):212-8. PubMed ID: 7620691
[TBL] [Abstract][Full Text] [Related]
8. [The hemodynamic effects of a treatment with beta-receptor blockers during coronary surgery. A comparison between acebutolol and esmolol].
Kling D; Boldt J; Zickmann B; Dapper F; Hempelmann G
Anaesthesist; 1990 May; 39(5):264-8. PubMed ID: 1972611
[TBL] [Abstract][Full Text] [Related]
9. Use of an ultrashort-acting beta-receptor blocker (esmolol) in patients with acute myocardial ischemia and relative contraindications to beta-blockade therapy.
Kirshenbaum JM; Kloner RF; McGowan N; Antman EM
J Am Coll Cardiol; 1988 Sep; 12(3):773-80. PubMed ID: 2900259
[TBL] [Abstract][Full Text] [Related]
10. Ultra short-acting intravenous beta-adrenergic blockade as add-on therapy in acute unstable angina.
Barth C; Ojile M; Pearson AC; Labovitz AJ
Am Heart J; 1991 Mar; 121(3 Pt 1):782-8. PubMed ID: 1672051
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics and pharmacokinetics of esmolol, a short-acting beta-blocking agent, in children.
Cuneo BF; Zales VR; Blahunka PC; Benson DW
Pediatr Cardiol; 1994; 15(6):296-301. PubMed ID: 7838803
[TBL] [Abstract][Full Text] [Related]
12. Symptomatic and hemodynamic recovery following dobutamine stress echo: benefit of low-dose esmolol administration.
Abdullah EE; Pollick C
Int J Card Imaging; 1997 Feb; 13(1):53-7. PubMed ID: 9080239
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of esmolol in unstable angina pectoris. European Esmolol Study Group.
Hohnloser SH; Meinertz T; Klingenheben T; Sydow B; Just H
Am J Cardiol; 1991 Jun; 67(16):1319-23. PubMed ID: 1675036
[TBL] [Abstract][Full Text] [Related]
14. Esmolol: a titratable short-acting intravenous beta blocker for acute critical care settings.
Turlapaty P; Laddu A; Murthy VS; Singh B; Lee R
Am Heart J; 1987 Oct; 114(4 Pt 1):866-85. PubMed ID: 2889341
[TBL] [Abstract][Full Text] [Related]
15. Esmolol in acute ischemic syndromes.
Mitchell RG; Stoddard MF; Ben-Yehuda O; Aggarwal KB; Allenby KS; Trillo RA; Loyd R; Chang CT; Labovitz AJ
Am Heart J; 2002 Nov; 144(5):E9. PubMed ID: 12422138
[TBL] [Abstract][Full Text] [Related]
16. Esmolol: a new ultrashort-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias.
Gray RJ; Bateman TM; Czer LS; Conklin CM; Matloff JM
J Am Coll Cardiol; 1985 Jun; 5(6):1451-6. PubMed ID: 2860148
[TBL] [Abstract][Full Text] [Related]
17. Hemodynamic interactions of a new beta blocker, celiprolol, with nifedipine in angina pectoris.
Silke B; Verma SP; Guy S
Cardiovasc Drugs Ther; 1991 Aug; 5(4):681-7. PubMed ID: 1679661
[TBL] [Abstract][Full Text] [Related]
18. Hemodynamic effects of celiprolol in patients with ischemic and non-ischemic cardiomyopathy.
Hennersdorf MG; Perings C; Vester EG
Int J Cardiol; 1999 Mar; 68(3):289-95. PubMed ID: 10213280
[TBL] [Abstract][Full Text] [Related]
19. Hemodynamic effects of esmolol, an ultrashort-acting beta blocker.
Askenazi J; MacCosbe PE; Hoff J; Turlapaty P; Hua TA; Laddu A
J Clin Pharmacol; 1987 Aug; 27(8):567-73. PubMed ID: 2888793
[TBL] [Abstract][Full Text] [Related]
20. Celiprolol, a beta-adrenoceptor antagonist with vasodilator effect, improves hemodynamic response to catecholamine, spontaneous locomotor activity, and survival in cardiomyopathic hamsters with advanced heart failure.
Nakamura Y; Ryoke T; Tanaka N; Ohkusa T; Matsuzaki M
J Cardiovasc Pharmacol; 1998 Feb; 31(2):171-8. PubMed ID: 9475257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
